Cassava Sciences, Inc. announced that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. Dr. Friedmann was an esteemed member of Board of Directors since 1998 and an Officer of the Company since 2001. He was also a force of nature in drug development, with eight drug approvals to his name and authorship on countless scientific papers and patents.

Prior to joining Cassava Sciences, he served as President & CEO of Daiichi Pharmaceutical Corp. and held senior leadership positions with Johnson & Johnson in R&D, including Head of Biotechnology Research. James W. Kupiec, MD, who has been serving as Chief Clinical Development Officer of Cassava Sciences, will now serve as Chief Medical Officer for the Company, effective immediately.